vs

Side-by-side financial comparison of ImmunityBio, Inc. (IBRX) and NaaS Technology Inc. (NAAS). Click either name above to swap in a different company.

ImmunityBio, Inc. is the larger business by last-quarter revenue ($38.3M vs $25.9M, roughly 1.5× NaaS Technology Inc.). ImmunityBio, Inc. runs the higher net margin — -161.8% vs -193.3%, a 31.5% gap on every dollar of revenue. On growth, ImmunityBio, Inc. posted the faster year-over-year revenue change (407.0% vs 121.2%).

ImmunityBio, Inc. is a clinical-stage biotechnology company focused on developing next-generation immunotherapies and vaccine candidates targeting multiple cancer types and infectious diseases. It operates mainly in the U.S. market, with core R&D segments including cell therapy, antibody therapeutics, and targeted vaccine platforms designed to enhance patient treatment outcomes.

NaaS Technology Inc. is a leading electric vehicle energy service provider based in China. It delivers one-stop solutions covering charging network operation, software and hardware support for charging station operators, and value-added services such as charging location search and payment for EV owners, serving both enterprise and individual customers across domestic and select overseas markets.

IBRX vs NAAS — Head-to-Head

Bigger by revenue
IBRX
IBRX
1.5× larger
IBRX
$38.3M
$25.9M
NAAS
Growing faster (revenue YoY)
IBRX
IBRX
+285.7% gap
IBRX
407.0%
121.2%
NAAS
Higher net margin
IBRX
IBRX
31.5% more per $
IBRX
-161.8%
-193.3%
NAAS

Income Statement — Q4 FY2025 vs Q2 FY2024

Metric
IBRX
IBRX
NAAS
NAAS
Revenue
$38.3M
$25.9M
Net Profit
$-61.9M
$-50.0M
Gross Margin
99.0%
29.2%
Operating Margin
-169.0%
-144.2%
Net Margin
-161.8%
-193.3%
Revenue YoY
407.0%
121.2%
Net Profit YoY
-4.7%
18.4%
EPS (diluted)
$-0.06
$-0.02

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
IBRX
IBRX
NAAS
NAAS
Q4 25
$38.3M
Q3 25
$32.1M
Q2 25
$26.4M
Q1 25
$16.5M
Q4 24
$7.6M
Q3 24
$6.1M
Q2 24
$25.9M
Net Profit
IBRX
IBRX
NAAS
NAAS
Q4 25
$-61.9M
Q3 25
$-67.3M
Q2 25
$-92.6M
Q1 25
$-129.6M
Q4 24
$-59.2M
Q3 24
$-85.7M
Q2 24
$-50.0M
Gross Margin
IBRX
IBRX
NAAS
NAAS
Q4 25
99.0%
Q3 25
99.4%
Q2 25
99.5%
Q1 25
99.6%
Q4 24
Q3 24
Q2 24
29.2%
Operating Margin
IBRX
IBRX
NAAS
NAAS
Q4 25
-169.0%
Q3 25
-173.5%
Q2 25
-269.8%
Q1 25
-390.1%
Q4 24
-919.0%
Q3 24
-1314.3%
Q2 24
-144.2%
Net Margin
IBRX
IBRX
NAAS
NAAS
Q4 25
-161.8%
Q3 25
-209.8%
Q2 25
-350.3%
Q1 25
-784.9%
Q4 24
-783.4%
Q3 24
-1404.0%
Q2 24
-193.3%
EPS (diluted)
IBRX
IBRX
NAAS
NAAS
Q4 25
$-0.06
Q3 25
$-0.07
Q2 25
$-0.10
Q1 25
$-0.15
Q4 24
$-0.08
Q3 24
$-0.14
Q2 24
$-0.02

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
IBRX
IBRX
NAAS
NAAS
Cash + ST InvestmentsLiquidity on hand
$242.8M
$24.7M
Total DebtLower is stronger
Stockholders' EquityBook value
$-500.5M
$-33.4M
Total Assets
$501.9M
$180.2M
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
IBRX
IBRX
NAAS
NAAS
Q4 25
$242.8M
Q3 25
$257.8M
Q2 25
$153.7M
Q1 25
$61.6M
Q4 24
$149.8M
Q3 24
$130.4M
Q2 24
$24.7M
Stockholders' Equity
IBRX
IBRX
NAAS
NAAS
Q4 25
$-500.5M
Q3 25
$-524.3M
Q2 25
$-570.7M
Q1 25
$-591.4M
Q4 24
$-489.1M
Q3 24
$-745.1M
Q2 24
$-33.4M
Total Assets
IBRX
IBRX
NAAS
NAAS
Q4 25
$501.9M
Q3 25
$519.0M
Q2 25
$402.1M
Q1 25
$303.8M
Q4 24
$382.9M
Q3 24
$364.6M
Q2 24
$180.2M

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
IBRX
IBRX
NAAS
NAAS
Operating Cash FlowLast quarter
$-70.4M
$-25.7M
Free Cash FlowOCF − Capex
$-71.3M
FCF MarginFCF / Revenue
-186.2%
Capex IntensityCapex / Revenue
2.4%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$-308.8M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
IBRX
IBRX
NAAS
NAAS
Q4 25
$-70.4M
Q3 25
$-68.9M
Q2 25
$-79.7M
Q1 25
$-85.9M
Q4 24
$-85.1M
Q3 24
$-98.8M
Q2 24
$-25.7M
Free Cash Flow
IBRX
IBRX
NAAS
NAAS
Q4 25
$-71.3M
Q3 25
$-69.6M
Q2 25
$-80.8M
Q1 25
$-87.0M
Q4 24
$-87.3M
Q3 24
$-101.6M
Q2 24
FCF Margin
IBRX
IBRX
NAAS
NAAS
Q4 25
-186.2%
Q3 25
-217.2%
Q2 25
-305.9%
Q1 25
-526.9%
Q4 24
-1155.4%
Q3 24
-1663.2%
Q2 24
Capex Intensity
IBRX
IBRX
NAAS
NAAS
Q4 25
2.4%
Q3 25
2.3%
Q2 25
4.1%
Q1 25
6.8%
Q4 24
28.0%
Q3 24
45.7%
Q2 24

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons